Our Science
programs
Our lead program is CU-13001, a 15-LO inhibitor. This is complemented by a robust ion channel portfolio featuring the T-type CaV3.x modulator CU-00048 and the selective CaV3.2 program CU-00213. All programs leverage our proprietary biomarker platform anchored by Miro1.
We are developing best-in-class therapies designed to target the underlying drivers of Parkinson’s disease, Essential Tremor, Amyotrophic Lateral Sclerosis, and Friedreich’s Ataxia.
PARTNER WITH ACUREX
VALIDATED PHARMACOLOGY
We drive capital‑efficiency by target validation, biomarker integration, and translational clarity in the clinic, prioritizing assets with favorable safety and optimized pharmacokinetics. This approach yields superior performance: CU‑13001 outperforms direct LRRK2 kinase inhibitors by preventing synuclein pathology and suppressing neuroinflammation, while CU‑00048 defines a new standard for efficacy in T‑type modulation.
